FeesSafety
Pluang+

U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

Market News
24 Oct 2026
Tokenpost
View Source
Bullish
U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

Since August, U.S. spot Bitcoin exchange-traded funds (ETFs) have attracted about $6.4 billion in net inflows, significantly more than the roughly $1.5 billion in Bitcoin purchases by corporate treasuries. BlackRock’s IBIT ETF led with around $6 billion in inflows. This surge in ETF buying comes as U.S. producer prices rose 1.3% in September, the largest monthly increase since March 2022, and futures markets price in nearly an 80% chance of a Federal Reserve rate hike in December. These factors suggest investors are shifting toward Bitcoin ETFs amid expectations of tighter monetary policy.

The story about U.S. spot Bitcoin ETFs and corporate treasury Bitcoin purchases is presented here with market data from Pluang. For readers following cryptocurrency markets, as of Oct 24, 2026 18:51 WIB, only 6 of 50 major cryptocurrencies rose while 43 fell. Among notable movers, SAND dropped 5.32% to Rp909 with a typical hold time of 124 days and 60% sell activity, contrasting with SNX which fell 5.18% to Rp3.660 but had 100% buy activity and a shorter hold time of 70 days. UNI also declined 5.08% to Rp123.325 with nearly balanced sell and buy orders.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Tether's Mining Development Kit gains support from 15 mining firms to unify Bitcoin mining tools.

Tether's Mining Development Kit gains support from 15 mining firms to unify Bitcoin mining tools.

Tether has announced that 15 mining operators, ASIC manufacturers, and mining pools have committed to integrating with its open-source Mining Development Kit (MDK). The MDK aims to solve compatibility issues in Bitcoin mining by providing a unified f...

Protocol Fundamentals
Bullish
4 hours ago
Aave (AAVE) price drops 5.29% to $140.12, dipping below key technical support levels.

Aave (AAVE) price drops 5.29% to $140.12, dipping below key technical support levels.

Aave (AAVE) experienced a 5.29% decline over 24 hours, falling to $140.12 as of early Saturday. This price slipped 51 cents below the lower Bollinger Band level of $140.63, a technical indicator noted on October 22. The chart also showed a relative s...

Technical Signals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App